Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A. is dated November 13, 2025. The report serves to incorporate by reference a press release (Exhibit 99.1) issued on the same date into the company's registration statements on Form F-3 and Form S-8. The filing is signed by Jonathan Dickinson, Chief Executive Officer.
Key Financial Metrics
The provided filing text does not contain specific financial data. No values for revenue, profit, cash flow, margins, debt, or liquidity are disclosed in this document.
Material Changes
The filing text does not provide information regarding material changes versus prior comparable periods.
Guidance, Outlook, and Risks
The document references a press release but explicitly excludes a quotation from the Chief Executive Officer from the incorporation by reference. Consequently, no specific guidance, outlook, management commentary, risks, contingencies, or unusual items are detailed in the provided text.
Investor Verification Checklist
- Review the full text of Exhibit 99.1 (Press Release dated November 13, 2025) for the specific announcement details omitted from this summary.
- Verify the impact of the press release on the company's registration statements (Form F-3 and Form S-8).
- Check subsequent filings for any financial updates or clarifications related to the November 13, 2025 announcement.